{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:21:25Z","timestamp":1787023285363,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T00:00:00Z","timestamp":1521763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognostic factors and the efficacy of first-line chemotherapy remain unclear in patients with advanced thymic carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a multi-institutional retrospective study named NEJ023 for patients with advanced thymic carcinoma. All patients without any indication of curative treatment were treated with chemotherapy from 1995 to 2014 at 40 institutions of the North East Japan Study Group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 286 patients with advanced thymic carcinoma were analyzed. First-line chemotherapy included platinum-based doublets in 62.2% of the patients, monotherapy in 3.5%, and other multidrug chemotherapy (e.g., cisplatin, doxorubicin, vincristine, and cyclophosphamide [ADOC]) in 34.3%. The median follow-up period was 55.5 months, and the median overall survival (OS) from the start of first-line chemotherapy was 30.7 months (95% confidence interval, 25.9\u201335.9 months). There was no significant difference in OS among different first-line chemotherapy regimens (e.g., between carboplatin\/paclitaxel and ADOC, median OS: 27.8 vs. 29.9 months). Masaoka-Koga stage IVa and volume reduction surgery were favorable prognostic factors for OS in the multivariate analysis using the Cox proportional hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The efficacy of each first-line chemotherapy regimen for advanced thymic carcinoma did not vary significantly. Our results might support the adequacy of the use of carboplatin\/paclitaxel as first-line chemotherapy for these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Because of its rarity, there is limited information about prognostic factors and efficacy of chemotherapy in patients with advanced thymic carcinoma. This is the largest data set for those patients treated with chemotherapy. This study suggests there is no significant difference in efficacy between carboplatin\/paclitaxel and cisplatin\/doxorubicin\/vincristine\/cyclophosphamide for advanced thymic carcinoma. This result can support the adequacy of the selection of platinum doublets as treatment for those patients, rather than anthracycline-based multidrug regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0586","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T12:16:49Z","timestamp":1521721009000},"page":"1210-1217","source":"Crossref","is-referenced-by-count":26,"title":["Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study"],"prefix":"10.1093","volume":"23","author":[{"given":"Ryo","family":"Ko","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehito","family":"Shukuya","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tateishi","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ohta, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Iwasawa","sequence":"additional","affiliation":[{"name":"Department of Respirology, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Azuma","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Muraki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Juntendo University Urayasu Hospital, Urayasu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Hiroshima Red Cross & Atomic-bomb Survivors Hospital, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Takashima","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayo","family":"Soda","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ishimoto","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nukiwa","sequence":"additional","affiliation":[{"name":"Japan Anti-Tuberculosis Association, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"North East Japan Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,23]]},"reference":[{"key":"2021122511130594600_onco12420-bib-0001","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"2021122511130594600_onco12420-bib-0002","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"2021122511130594600_onco12420-bib-0003","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.athoracsur.2012.09.006","article-title":"Thymic carcinoma: A multivariate analysis of factors predictive of survival in 290 patients","volume":"95","author":"Weksler","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"2021122511130594600_onco12420-bib-0004","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1002\/cncr.10588","article-title":"Treatment and prognosis of thymic carcinoma: A retrospective analysis of 40 cases","volume":"94","author":"Ogawa","year":"2002","journal-title":"Cancer"},{"key":"2021122511130594600_onco12420-bib-0005","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/cncr.11606","article-title":"Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is effective treatment for advanced thymic carcinoma","volume":"98","author":"Yoh","year":"2003","journal-title":"Cancer"},{"key":"2021122511130594600_onco12420-bib-0006","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2021122511130594600_onco12420-bib-0007","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"2021122511130594600_onco12420-bib-0008","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","article-title":"Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma","volume":"67","author":"Igawa","year":"2010","journal-title":"Lung Cancer"},{"key":"2021122511130594600_onco12420-bib-0009","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511130594600_onco12420-bib-0010","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jjco\/hyr089","article-title":"Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer","volume":"41","author":"Furugen","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"2021122511130594600_onco12420-bib-0011","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lungcan.2011.05.013","article-title":"Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: Evaluation of efficacy and toxicity","volume":"74","author":"Okuma","year":"2011","journal-title":"Lung Cancer"},{"key":"2021122511130594600_onco12420-bib-0012","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122511130594600_onco12420-bib-0013","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer Group Study 0803. J","volume":"9","author":"Inoue","year":"2014","journal-title":"Thorac Oncol"},{"key":"2021122511130594600_onco12420-bib-0014","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/1759-7714.12300","article-title":"Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity","volume":"7","author":"Luo","year":"2016","journal-title":"Thoracic Cancer"},{"key":"2021122511130594600_onco12420-bib-0015","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6004\/jnccn.2013.0072","article-title":"Thymomas and thymic carcinomas: Clinical practice guidelines in oncology","volume":"11","author":"Ettinger","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122511130594600_onco12420-bib-0016","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/JTO.0b013e3181653c71","article-title":"Thymic carcinoma: 30 cases at a single institution","volume":"3","author":"Yano","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2021122511130594600_onco12420-bib-0017","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/JTO.0000000000000660","article-title":"Impact of positive nodal metastases in patients with thymic carcinoma and thymic neuroendocrine tumors","volume":"10","author":"Weksler","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"suppl 4","key":"2021122511130594600_onco12420-bib-0018","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","author":"Masaoka","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2021122511130594600_onco12420-bib-0019","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2012.12.012","article-title":"Clinical outcomes with chemotherapy for advanced thymic carcinoma","volume":"80","author":"Okuma","year":"2013","journal-title":"Lung Cancer"},{"key":"2021122511130594600_onco12420-bib-0020","first-page":"145","author":"Travis","year":"2004"},{"key":"2021122511130594600_onco12420-bib-0021","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1097-0142(19911101)68:9<1984::AID-CNCR2820680923>3.0.CO;2-P","article-title":"A tentative tumor-node-metastasis classification of thymoma","volume":"68","author":"Yamakawa","year":"1991","journal-title":"Cancer"},{"key":"2021122511130594600_onco12420-bib-0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauser","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122511130594600_onco12420-bib-0023","doi-asserted-by":"crossref","first-page":"775","DOI":"10.6061\/clinics\/2015(12)03","article-title":"Chemotherapy and prognosis in advanced thymic carcinoma patients","volume":"70","author":"Song","year":"2015","journal-title":"Clinics"},{"key":"2021122511130594600_onco12420-bib-0024","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2009.11.057","article-title":"Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma","volume":"89","author":"Hosaka","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"2021122511130594600_onco12420-bib-0025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ejcts\/ezu277","article-title":"A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma","volume":"47","author":"Hamaji","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"issue":"suppl 2","key":"2021122511130594600_onco12420-bib-0026","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG thymic epithelial tumors staging project: Proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J Thorac Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0586","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/10\/1210\/41916177\/oncolo_23_10_1210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/10\/1210\/41916177\/oncolo_23_10_1210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:14:12Z","timestamp":1640412852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/10\/1210\/6439708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,23]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,3,23]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0586","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10,1]]},"published":{"date-parts":[[2018,3,23]]}}}